PUNE, India, June 16, 2016 /PRNewswire/ --
ReportsnReports.com adds "Thrombocytopenia - Pipeline Review, H1 2016" market research report complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombocytopenia and special features on late-stage and discontinued projects.
Complete report on H1 2016 pipeline review of Thrombocytopenia with 52 market data tables and 15 figures, spread across 178 pages is available at http://www.reportsnreports.com/reports/594620-thrombocytopenia-pipeline-review-h1-2016.html .
The report also reviews key players involved in the therapeutic development for Thrombocytopenia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies discussed in this Thrombocytopenia Pipeline Review, H1 2016 report include 3SBio Inc., Amarillo Biosciences, Inc., Amgen Inc., Baxalta Incorporated, Bayer AG, BioLineRx, Ltd., Boehringer Ingelheim GmbH, Bolder Biotechnology, Inc., Bristol-Myers Squibb Company, Cellerant Therapeutics, Inc., Eisai Co., Ltd., Genosco, Hansa Medical AB, Immunomedics, Inc., Intas Pharmaceuticals Ltd., Jiangsu Hengrui Medicine Co., Ltd., Merck & Co., Inc., Momenta Pharmaceuticals, Inc., Myelo Therapeutics GmbH, Neumedicines Inc., Novartis AG, Pfizer Inc., PhytoHealth Corporation, Prophylix Pharma AS, Protalex, Inc., Rigel Pharmaceuticals, Inc., Shionogi & Co., Ltd., STATegics, Inc., UCB S.A. and ViroMed Co., Ltd.
Order a purchase copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=594620 .
Drug Profiles discussed in this research are Antibody for Autoimmune Disorders and Inflammation, avatrombopag, BBT-059, BI-655064, BL-8040, BMS-986004, CLT-009, eltrombopag olamine, fostamatinib disodium, GL-2045, GSK-2285921, Hetrombopag Olamine, interferon alfa, lusutrombopag, MK-8723, Monoclonal Antibody to Agonize TpoR for Thrombocytopenia, Monoclonal Antibody to Antagonize FcgR1 for Inflammatory and Autoimmune Disorders, Myelo-001, NMIL-121 , Oligonucleotides to Activate miRNA-150 for Thrombocytopenia and Anemia, PBF-1509, PEG-VM501, PHN-013, PRTX-100, Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases, rivaroxaban, romiplostim, romiplostim biosimilar, SKIO-703, SM-101, Small Molecules to Inhibit BLVRB for Thrombocytopenia, Small Molecules to Inhibit PF4 for Heparin Induced Thrombocytopenia, STST-4, thrombopoietin, Tromplate, TXA-302, UCB-7665 and veltuzumab.
Scope of this report: The report provides a snapshot of the global therapeutic landscape of Thrombocytopenia and reviews pipeline therapeutics for Thrombocytopenia by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Thrombocytopenia therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Thrombocytopenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Thrombocytopenia.
Another newly published market research report titled on Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2016 provides comprehensive information on the therapeutic development for Leishmaniasis (Kala-Azar), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leishmaniasis (Kala-Azar) and special features on late-stage and discontinued projects. Companies discussed in this research are Advinus Therapeutics Ltd., Anacor Pharmaceuticals, Inc., BioLingus AG, Dafra Pharma International Ltd., iCo Therapeutics Inc., ManRos Therapeutics, Matinas BioPharma Holdings, Inc., Mologen AG, Nanomerics Ltd, Takeda Pharmaceutical Company Limited and Zydus Cadila Healthcare Limited. Leishmaniasis (Kala-Azar) Pipeline market research report of 113 pages is available at http://www.reportsnreports.com/reports/523430-leishmaniasis-kala-azar-global-clinical-trials-review-h1-2016.html .
Explore more reports on Pharmaceuticals.
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
Connect With Us on:
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
+1 888 391 5441